Key result
Small-molecule therapies offer promising new avenues for the management of angina in the elderly, though an individualized approach is critical due to drug intolerance and frailty.
Why the study?
Angina prevalence is growing in aging populations where management is challenged by drug intolerance, resistance, and frailty, yet new small-molecule therapies have rarely focused specifically on the elderly.
Do small-molecule therapies improve the management of angina pectoris in the elderly?
Do small-molecule therapies improve the management of angina pectoris in the elderly?
Emerging small-molecule therapies offer promising new avenues for managing angina in the elderly, though further research specifically targeting this population is needed.
Supports cautious individualized use in frail elderly; leaves open need for targeted trials.
Introduction: As our population ages, the prevalence of angina is growing, leading to increased morbidity and decreased quality of life. The management of angina in the elderly is challenging due to drug intolerance and/or drug resistance as well as frailty. Over the past decades, many new therapeutic small molecules have been investigated for the management of angina. Although none of these studies have specifically focused on the therapies for the elderly, they offer promising new avenues for the treatment of angina in the elderly.Areas covered: Herein, the authors provide a review of the recently published literature on the use of small-molecule therapies for angina management in the elderly and provide a brief overview of these therapies.Expert opinion: A variety of therapeutic classes of existing and newer small molecules are emerging for the management of angina in the elderly. An individualized approach to the management of angina in this growing population is critical for good outcomes. Many small molecules are in their initial stages of clinical use, and further research should be conducted on their utility, especially in the elderly.
No takes yet. Share an insight, caveat, or question.
Waheed et al. (2019) conducted a review in Angina pectoris. Small-molecule therapies was evaluated. Small-molecule therapies offer promising new avenues for the management of angina in the elderly, though an individualized approach is critical due to drug intolerance and frailty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: